ANN ARBOR, Mich., March 5, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced a major milestone in “Project Atlas”, the Company’s next-generation bioengineering initiative aimed at creating entirely new classes of materials for industrial and defense applications.

Kraig Labs first disclosed the existence of Project Atlas on January 19^th, 2026, when it was already at an advanced stage of development. The Company described an ambitious effort to merge numerous complex genetic elements into a single integrated architecture. Project Atlas seeks to create new super materials with enhanced strength, toughness, and other properties. Today, Kraig Labs confirms Project Atlas has passed its most critical milestone and is moving forward at full speed.

Project Atlas employs numerous genetic modifications operating in tandem to create an entirely new class of materials. The result is a powerful new approach to biomaterial development, opening the door to entirely new performance capabilities.

“This project represents what I believe is the most advanced molecular biology work ever undertaken in material science,” said Kim Thompson, Founder and CEO of Kraig Labs. “We are creating an advanced platform, where multiple components work in unison to achieve very specific material outcomes. That level of coordinated engineering has never been attempted before in spider silk or biomaterials, to our knowledge.”

Atlas has already resulted in the creation of multiple new transgenic lines, which are now progressing through the Company’s evaluation pipeline.

Early results have reinforced management’s confidence that Project Atlas will reshape the future of biomaterial development and significantly broaden the applications for spider silk and other super fibers.

This latest breakthrough comes as Kraig Labs continues to receive global recognition for its pioneering work in bioengineered spider silk. The Company was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of its work in bioengineering and scaling spider silk production.

**

With Project Atlas now moving into its next phase, Kraig Labs expects continued rapid progress as the program advances toward the creation of new materials designed to meet demanding industrial and defense performance requirements.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

** Photography by Mark Thiessen, NGM Staff, Image Copyright: National Geographic Magazine

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., February 23, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that its groundbreaking work in commercializing spider silk is featured on the cover of the March 2026 issue of National Geographic magazine.

National Geographic highlights Kraig Labs’ advancements in producing spider silk fibers using genetically enhanced silkworms. The article includes a graphic that describes the significant advantages of a silkworm-based platform (Kraig Labs Technology). Those advantages include being the most cost-efficient and highest-quality technology for commercializing spider silk. This breakthrough approach combines the scalability of silkworm cultivation with the exceptional performance properties of spider silk. The feature explores both the technical advantages of Kraig’s approach and the growing commercial opportunities of spider silk biomaterials.

Being recognized by a publication with the global reach and historic legacy of National Geographic represents a major milestone for Kraig Labs and for the broader field of biomaterials innovation.

Kraig Labs hosted a team from National Geographic at the Company’s research center for three days of interviews, facility tours, and photography. That visit resulted in the striking cover image and an in-depth feature exploring the science and progress behind next-generation spider silk materials. During their visit, Kraig Labs recombinant spider silk was put to the test, towing a car across a parking lot and suspending a person from the ceiling on a single 0.35-ounce loop of thread. 

Due to strict confidentiality and publication agreements, the Company was unable to discuss this publicly until the issue was officially released. Kraig Labs is now proud to share this achievement with its shareholders and partners.

Kraig Labs extends its sincere thanks to the entire National Geographic editorial and photography team for their professionalism and dedication in bringing this story to a global audience.

**

“We are honored to have our work recognized by one of the world’s most respected publications. Our recombinant spider silk technology holds amazing potential across numerous applications from apparel to medicines, industry, and defense technologies,” said Kim Thompson, Kraig Labs CEO, founder, and inventor of the technology. “With our production operations set to kick into high gear, our team is eager to begin supplying the markets with this amazing material.”

Kraig Labs continues to advance commercialization of its recombinant spider silk technologies as global interest grows in high-performance, sustainable fiber and fabric solutions.

Interested persons can order a copy of the magazine from National Geographic at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

** Photography by Mark Thiessen, NGM Staff, Image Copyright: National Geographic Magazine

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., February 17, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that its 2026 production plan has officially moved from strategy to execution.

The Company has now moved bio-material to incubation, getting a jumpstart on its March production plan and formally initiating its multi-ton spider silk scale-up initiative.

This milestone follows Kraig’s recently announced 2026 production schedule. This aggressive plan is set to achieve sustained monthly production of recombinant spider silk cocoons at unprecedented commercial volumes. With the release of the first wave of production materials now complete, Kraig Labs has activated its expanded manufacturing pipeline and commenced field-level implementation.

“This is the moment where planning becomes production,” said Kim Thompson, Kraig Labs CEO and Founder. “Our 2026 roadmap was built around disciplined expansion, operational efficiency, and multi-ton output. Today, that roadmap is in motion. Bio-materials have recently been moved to incubation in preparation for the March production run.”

The March production run represents the first major deployment under the Company’s 2026 plan. The initiative is designed to drive consistent output at levels never before seen, while reinforcing quality control, supply chain stability, and downstream processing capacity.

By initiating this production cycle, Kraig Labs is delivering on its commitment, creating the world’s first reliable, repeatable, and scalable commercial spider silk manufacturing. The Company’s vertically integrated model enables rapid deployment of materials, controlled expansion of silkworm rearing operations, and alignment with future customer demand.

“Our focus is clear,” Thompson continued. “Execution. Volume. Commercialization. Every production cycle strengthens our position as the global leader in recombinant spider silk.”

Kraig Labs expects this March run to set the pace for subsequent production cycles throughout 2026, forming the foundation for sustained monthly metric-ton-level spider silk production.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

2026 Production Plan Set for a record 10 Metric Tons of Recombinant Spider Silk Cocoon Per Month

ANN ARBOR, Mich., February 9, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced its 2026 production plan that will drive explosive growth and establish a new global benchmark for spider silk manufacturing.

Kraig’s technology is built upon the use of modified silkworms to produce recombinant spider silk. Within the next 30 days, the Company will begin large-scale deployment of its stockpile of proprietary spider silk silkworm eggs. Production plans are now fully in place. Release is scheduled to begin the first week of March. Spider silk output is expected to ramp rapidly, with Kraig Labs hitting full output of 10 metric tons of recombinant spider silk cocoon per month by May.

At full capacity, this level of sustained spider silk output represents a scale that has never been seen before. No company has ever operated anywhere close to this volume of naturally spun recombinant spider silk. This production program is a true game changer for the commercialization of spider silk and firmly positions Kraig Labs as the world leader in this field.

Kraig Labs is committed to sustaining this operational capacity with plans for adding even more production capacity later in 2026.

Kraig Labs has engineered and refined proprietary production strains designed for durability, consistency, and high yields of recombinant spider silk. These production lines have been advanced through repeated rearing cycles to ensure stability, resilience, and dependable performance at an industrial scale.

In parallel, the Company has made substantial investments in facilities, workforce expansion, and vertically integrated production infrastructure. Together, these elements form a manufacturing platform built for scale and execution. Kraig Labs has unlocked an entirely new standard for spider silk production.

“This is the most exciting and ambitious program for spider silk production the world has ever seen. Achieving multi-ton level output unlocks key markets and sales channels,” said Kim Thompson, Founder and CEO of Kraig Labs. “We are setting standards for spider silk production that were previously thought unreachable. This is a defining moment for our Company and spider silk technology. We believe this will be a transformative moment for Kraig Labs and the commercialization of spider silk.”

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., January 19, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it is entering the new year with the implementation of the most ambitious and advanced genetic engineering initiative ever undertaken by the Company. The focus of this project is to dramatically increase strength and elasticity beyond anything ever seen in the area of recombinant spider silk.

The Company reported that its research and development team has successfully completed the construction phase of the most advanced spider silk gene constructs in Kraig’s history. With this milestone achieved, Kraig Labs has now begun the active execution phase of what represents the next evolution in silkworm gene engineering and recombinant spider silk production.

This initiative, now well underway, represents the largest and most complex silkworm gene-engineering project ever undertaken globally. The program builds upon years of proprietary research and production experience and is designed to further expand the performance, scalability, and commercial potential of the Company’s spider silk technologies.

“This project represents a defining moment for our technology platform,” said Kim Thompson, Founder and CEO of Kraig Labs. “Our team has completed the most sophisticated spider silk gene constructs we have ever developed, and we are now advancing into the next phase, creating new materials that we believe will significantly expand the boundaries of what is possible in spider silk production. I believe this is the most ambitious application of genetic engineering to material science in world history and that this work will eclipse anything else being done in biomimicry or applications of molecular biology to material science.”

The new genetic engineering program is intended to drive continued innovation across the Company’s production pipeline, supporting enhanced fiber performance and future product diversification. Kraig Labs expects this effort to further strengthen its leadership position as it advances toward sustained commercial-scale spider silk manufacturing.

“This initiative reflects the depth of our expertise and our long-term commitment to innovation,” Thompson added. “As we continue to advance commercialization of our current product offerings, we are simultaneously investing in the technologies that will define the next generation of spider silk.”

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., January 12, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has taken possession of its third silkworm rearing center, completing the core physical infrastructure upgrades, underpinning the Company’s massive recombinant spider silk production scale-up planned for 2026.

This newest facility represents the final major component of the Company’s multi-year production expansion strategy. With three fully operational rearing centers, Kraig Labs will be able to run three simultaneous production cycles, providing both production diversity and the capacity required to meet and exceed one metric ton of finished spider silk per month.

This production scale-up, now well underway, is the culmination of years of development and refinement. Each element of the Company’s expansion, including facility design, staffing, geographic location, operational workflows, and training programs, has been optimized based on lessons learned from prior production campaigns.

The newly acquired facility is the largest single-site rearing center the Company has ever operated. This new facility is designed to support significantly higher throughput while maintaining the operational discipline and biological consistency required for large-scale spider silk manufacturing. This facility is expected to unlock the next level of production capacity as the Company rapidly accelerates spider silk output.

Importantly, this new rearing center has been strategically positioned to leverage the Company’s recently acquired mulberry fields, which will supply the expanded feedstock necessary to support this substantial increase in silkworm and spider silk production. These mulberry resources form a critical foundation of the Company’s vertically integrated production model and are expected to play a key role in enabling continuous, high-volume operations across all of its facilities.

The Company is now bringing this new rearing center online and expects to begin operations later this quarter.

“This milestone represents a critical step forward in our evolution as a world-leading supplier of spider silk,” said Kim Thompson, Kraig Labs Founder and CEO. “With this final rearing center secured and supported by expanded mulberry cultivation, we now have the infrastructure and feedstock capacity in place to support continuous, scalable production at levels that position Kraig Labs to fulfill our vision of commercially scalable and cost-effective spider silk production.”

The Company expects to provide additional updates as the facility is commissioned and fully integrated into its 2026 production campaign.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., January 7, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has taken possession of three critical mulberry fields for which it previously secured usage rights. The Company has now integrated this new feedstock capacity directly into the ramp-up of its current spider silk production.

With these fields now dedicated solely to its operational use, Kraig Labs has implemented an aggressive production scale-up slated to dramatically advance spider silk production and prepare silk needed to fulfill outstanding materials requests. Mulberry leaf from these fields is now being incorporated into active silkworm rearing cycles, strengthening the Company’s operations and enabling the deployment of more than 1,000,000 BAM-1 Alpha (“Alpha”) production hybrid eggs now scheduled for release.

“This marks an important operational milestone as we scale production,” said Kim Thompson, Founder and CEO of Kraig Labs. “By taking possession of these mulberry fields and integrating them into our production system, we are reinforcing the infrastructure needed to support continuous large-scale silkworm rearing and sustained spider silk manufacturing.”

The proximity of the mulberry fields to Kraig’s production facilities provides logistical efficiencies while enhancing feedstock consistency and supply security. This integration further supports the Company’s vertically coordinated approach to industrializing recombinant spider silk.

In addition to these fields, dedicated solely to the Company’s use and operations, Kraig Labs can access additional mulberry fields through its collaboration with a key government office in Southeast Asia. This, in turn, allows for rapid growth and expansion, removing fixed capacity constraints.

This development comes as Kraig Labs continues to expand production of its Alpha spider silk hybrids and advances towards sustained commercial output across performance textile and other high-value markets.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Merry Christmas, Happy Hanukkah, and Season’s Greetings to all our Shareholders.

Dear Shareholders

The other morning, I came across an article published on RealClearScience about the Christmas spider. This is a tale from Eastern Europe about a spider who spins a beautiful web in a family’s home on Christmas Eve. The glistening web then transforms to silver, a joy and blessing to the family, the value of which elevates them from poverty to prosperity[1].

I was vaguely aware of this story and had been gifted a small ornamental spider years ago, which is always hanging in my home. Reading that story this morning makes me think about the immediate future of Kraig Biocraft Laboratories and the blessings I believe we are poised to gift to the world over this coming year.

2025 was a year of growth and evolution for Kraig Labs. Together, we’ve achieved significant milestones that have strengthened our Company and positioned us for greater success in 2026.

This year kicked off with a series of operational and scientific breakthroughs that I believe will underpin a new year of growth and advancement across the core pillars of our business, spider silk production, end-market commercialization, and research and development of advanced materials.

Our R&D achievements in 2025 expanded both the breadth and depth of our technology platform. Early in the year, we announced the successful development of a recombinant Darwin Bark Spider silk, demonstrating our ability to engineer and express increasingly complex silk proteins with unique performance characteristics. We quickly followed this up with the creation of a Caddis Fly silk, opening the door to entirely new classes of biomaterials with potential for adhesion and underwater performance.

Our introduction of an advanced gene-splicing technology spurred the rapid pace of these developments. This work ultimately led Kraig Labs to a scientific breakthrough that set the world record, doubling the largest known gene insert in silkworm (opening the door for more advanced materials). Collectively, these advancements strengthen the technological foundation upon which all future new materials at Kraig Labs will be built.

2025 marked a stressful, yet pivotal, year in the evolution of our production operations. This year, we set a production record for advanced spider silk reeling utilizing automated reeling equipment – a key breakthrough needed to achieve multi-ton production. However, we fell short of our ultimate total production target.

In late 2025, we released the new BAM-1 ALPHA hybrid (“ALPHA”) that moved us fully into a true production diapausing hybrid. A huge advancement in production that we had been working on for years. 

The ALPHA hybrid produces the same recombinant spider silk as the original BAM-1.  The difference lies entirely in the background genetics that affect almost every other part of the silkworm, except the transgenic silk sequences.  In other words, ALPHA contains no altered transgenic traits from the original BAM-1.  What differentiates ALPHA from the original BAM-1 is that the parental strains (which both carry the original trans genes) are from a different lineage and are as distinct from the originals as a Golden Retriever is from a Rottweiler. 

The improved background genetics results in a critical 22% boost in silk yield compared to the parental strains. That 22% is very significant for increased production and commercialization. ALPHA also boasts improved reeling efficiency on automated machines, all while maintaining the same strength and materials performance, a game-changer for us in 2026.

To support the increased output of the ALPHA hybrids, we added parallel manufacturing facilities, allowing multiple production streams to operate simultaneously. The operational flexibility, capacity, and resilience of this model were key to our fourth-quarter production breakthrough. We’ve produced more than one million ALPHA eggs, which are ready for deployment to make finished spider silk yarn. These achievements reflect years of selective breeding and targeted design efforts that are now translating into meaningful scale and robustness.

Our accomplishments this year were not made alone. In 2025, we were granted operating licenses by two Southeast Asian countries, providing production security and diversification as we continue to leverage the capabilities of our new production spider silk transgenics. We also signed a strategic multi-year collaboration agreement with a key government agency in Southeast Asia, supporting our production growth and providing key resources, facilities, and land. This agreement was the result of several years of groundwork by our team to secure critical support and resources for our operations and the expansion of spider silk production. As we enter 2026, these collaborations are expanding with the granting of lease rights on additional mulberry gardens to supply our growing production capacity.

The addition of parallel manufacturing facilities and our strategic multi-country licensing expansion further diversified our production base, reduced operational risk, and positioned the Company for sustained, scalable growth across Southeast Asia.

Perhaps most exciting, 2025 marked the beginning of Kraig Labs’ transition from development to commercialization and spider silk sales. This year, we engaged with market leaders in the performance sportswear, sports equipment, and luxury fashion segments. The excitement from these segments to explore applications for our spider silk in their product offerings can now be met with near-term product capacity. In November, we secured our first commercial trial order, an important validation of both our technology and our readiness to serve customers in real-world applications. We believe this is just the first of many orders and opportunities for spider silk.

As we look toward 2026, we do so with growing excitement. The accomplishments of 2025, many of which are not yet reflected in our metrics, have built a rock-solid foundation for the years ahead. Our science is stronger, our production is larger and more resilient, our footprint is expanding, and early-stage commercialization is now underway.

On behalf of the entire Kraig Biocraft Laboratories team, we thank you for your patience, belief, and continued support. We look forward to sharing the next chapter of this journey with you.

From all of us at Kraig Biocraft Laboratories, we wish you a peaceful holiday season and a healthy, prosperous New Year. Warmest holiday greetings and sincere appreciation to you and yours.

With gratitude, resolve, and with the warmest wishes for a Merry Merry Christmas and Happy Hanukkah

Kim K. Thompson
Founder & Chief Executive Officer
On behalf of the entire Kraig Labs family

[1] https://www.zmescience.com/feature-post/culture/culture-society/christmas-spiders/

Breakthrough hybrid line continues to demonstrate superior resilience and scalability as the Company advances major production expansion initiatives

ANN ARBOR, Mich., December 15, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced the successful completion of its most recent production cycle, yielding more than one million BAM-1 Alpha hybrid eggs. These eggs are now staged for release over the next quarter and will serve as the next wave of recombinant spider silk production.

This milestone marks another decisive validation of the Company’s strategic transition to this more advanced spider silk line. The BAM-1 Alpha line has delivered greater uniformity and significantly greater resiliency throughout every phase of the production process. These gains directly translate into improved throughput, consistency, and reliability for the Company’s expanding spider silk manufacturing platform.

“The success of BAM-1 Alpha is reshaping our production capabilities,” said Kim Thompson, Founder and CEO of Kraig Labs. “These results reaffirm the power of this hybrid line, and to surpass the one-million-egg mark so quickly is further evidence that we are scaling efficiently, effectively, and in direct alignment with our commercial objectives.”

The rising production capacity enabled by BAM-1 Alpha is also fueling the Company’s accelerated expansion initiatives currently underway in Southeast Asia.

“With each new batch, we are strengthening the backbone of our commercial rollout,” Thompson continued. “The reliability and robustness of BAM-1 Alpha allow us to move forward quickly with confidence as we expand production.”

The Company has developed an aggressive production schedule for the next 6 months based on these exciting results and is already putting that plan into action.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., December 8, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that it has been granted usage rights to a significant block of government-owned mulberry gardens located near its spider silk production operations in Southeast Asia.

These land-use rights, granted to Kraig Labs by a key government agency as part of the Company’s collaborative relationship, will play a central role in Kraig Labs’ ongoing production expansion. The Company has agreed to pay a nominal rent for the use of the mulberry gardens. These mulberry gardens will provide the essential feedstock required to support the scaled-up of recombinant spider silk production. This added capacity will directly support the manufacturing of high-performance spider silk yarns targeted at performance textiles, technical apparel, and luxury fashion markets.

The newly secured acreage will provide a reliable and strategically positioned source of high-quality mulberry leaf, an essential input for maintaining production throughput and improved logistics. This alignment between land access, production capacity, and downstream processing is a key component of Kraig Labs’ strategic expansion blueprint.

Today’s announcement follows closely on the Company’s recently announced order from a leading performance sports apparel brand. Kraig Labs is currently finalizing materials for this customer’s pilot development program, which will utilize the Company’s recombinant spider silk fibers. The addition of these mulberry gardens strengthens Kraig Labs’ ability to meet future commercial demand as it advances toward broader market deployments.

“Access to these mulberry gardens marks another critical step in building an integrated and resilient production ecosystem for our spider silk technologies,” said Kim Thompson, Founder and CEO of Kraig Biocraft Laboratories. “Securing direct access to high-quality mulberry acreage gives us greater control over our supply chain and positions us to accelerate production of our BAM-1 Alpha hybrid spider silk. This collaboration with government stakeholders reflects their confidence in the economic and technological potential of our work.”

As this land is transferred to Kraig Labs’ control, the Company will prepare the gardens for incorporation into its expanding spider silk production pipeline. Additional staffing and operational resources will be deployed as part of the integration process, supporting both near-term production increases and the Company’s strategic vision for large-scale commercialization.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com